Interpharma Public Company Limited is a Thailand-based company that develops, researches and distributes healthcare products and beauty initiatives for human beings, and healthcare products for animals. The Company provides wellness and anti-aging products, aesthetic innovation products, companion animal health products and livestock products. Its products include PREBO, YUUU toothpaste, multivitamin, Probac 7, Probac 10, Beta Glucan Plus, Pure Krill Oil, Astacurmin, YUUU cleansing mousse, Perfectha Complement, Perfectha Derm, Perfectha Deep, Perfectha Subskin and Uderma.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	2.64B 79.11M 69.37M 63.94M 59.86M 112M 7.46B 115M 769M 297M 3.69B 297M 291M 12.79B	P/E 2024	52.3x	P/E 2025	22.8x
Enterprise Value	2.76B 82.69M 72.5M 66.83M 62.57M 117M 7.8B 120M 803M 311M 3.86B 310M 304M 13.37B	EV / Sales 2024	1.13x	EV / Sales 2025	1.31x
Free-Float	-	Yield 2024 *	-	Yield 2025	1.59%

05-11	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-02	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-01	Inter Pharma Public Company Limited announces Annual dividend, payable on May 25, 2026	CI
11-11	Inter Pharma Public Company Limited (SET:IP) agreed to acquire an additional 49% stake in Interpharma- ZEAvita Company Limited from Thai Union Ingredients.	CI
11-11	Inter Pharma Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-14	Inter Pharma Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-13	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-16	Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal	MT
25-04-16	Zhaoke Ophthalmology Limited Enters into Three Distribution and Supply Agreements with Interpharma Public Company Limited	CI
25-04-01	Inter Pharma Public Company Limited Signs Exclusive Distribution Agreement with Zhaoke Ophthalmology Company Limited for Comprehensive Eye Care Innovation	CI
25-02-25	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-25	Inter Pharma Public Company Limited Proposes to Omit Dividend Payment for the Year Ended December 31, 2024	CI
24-11-13	Inter Pharma Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

22-08-16	Inter Pharma : New shares of IP to be traded on August 18, 2022	PU
22-08-10	Inter Pharma Public : Notification on Change of Directors and Authorization of Directors	PU
22-08-10	Inter Pharma Public : Report on the results of sale of common shares offered to private placement (F53-5)	PU
22-08-10	Inter Pharma Public : Right Adjustment of IP-W1 (Edited)	PU
22-08-09	Inter Pharma Public : Right Adjustment of IP-W1	PU

Manager	Title	Age	Since
Trinnawat Thanitnithiphan CEO	Chief Executive Officer	56	2014-01-31
Chatkaew Krudkosol DFI	Director of Finance/CFO	56	2023-06-22
Chompunuch Meevang CMP	Compliance Officer	54	-

Director	Title	Age	Since
Napaporn Dechakarat BRD	Director/Board Member	51	2017-06-13
Sansanee Chaiyaroj BRD	Director/Board Member	64	2020-07-31
Trinnawat Thanitnithiphan BRD	Director/Board Member	56	2014-01-31

Inter Pharma Stock OTC Markets

Stocks

IPTB.F

TH9474010005

Pharmaceuticals

Valuation: Inter Pharma

Latest news : Inter Pharma

Press Releases: Inter Pharma

Managers and Directors: Inter Pharma

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTER PHARMA	-.--%	-.--%	-	-	79.11M
ELI LILLY AND COMPANY	+7.13%	+9.97%	+55.80%	+160.09%	1,077B
JOHNSON & JOHNSON	+3.99%	+11.50%	+67.09%	+55.96%	613B
ABBVIE INC.	+4.20%	+17.03%	+38.97%	+91.06%	448B
ROCHE HOLDING AG	+0.99%	+4.85%	+28.17%	+23.89%	332B
ASTRAZENECA PLC	+1.82%	+8.19%	+40.04%	+27.95%	293B
NOVARTIS AG	+0.22%	+6.75%	+31.30%	+42.34%	286B
NOVO NORDISK A/S	+0.73%	+8.53%	-27.33%	-39.55%	215B
AMGEN INC.	+1.56%	+6.14%	+29.30%	+60.97%	193B
GILEAD SCIENCES, INC.	+3.26%	+3.33%	+15.55%	+68.24%	159B
Average	+2.39%	+8.00%	+30.99%	+54.55%	401.79B
Weighted average by Cap.	+3.85%	+8.93%	+41.75%	+80.17%

	2024	2025
Net sales	1.91B 57.31M 50.25M 46.32M 43.36M 81.31M 5.41B 83M 557M 215M 2.67B 215M 211M 9.26B	2.21B 66.37M 58.19M 53.64M 50.22M 94.16M 6.26B 96.12M 645M 249M 3.09B 249M 244M 10.73B
Net income	37.28M 1.12M 980K 903K 845K 1.59M 105M 1.62M 10.85M 4.2M 52.1M 4.2M 4.1M 181M	122M 3.67M 3.22M 2.96M 2.78M 5.2M 346M 5.31M 35.63M 13.79M 171M 13.77M 13.47M 593M
Net Debt	209M 6.26M 5.49M 5.06M 4.74M 8.89M 591M 9.07M 60.83M 23.54M 292M 23.51M 23M 1.01B	119M 3.58M 3.14M 2.89M 2.71M 5.07M 337M 5.18M 34.74M 13.44M 167M 13.43M 13.13M 578M